Review



primary peripheral blood cd14 monocytes  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC primary peripheral blood cd14 monocytes
    Primary Peripheral Blood Cd14 Monocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 66 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+peripheral+blood+cd14+monocytes/pm41913215-62-0-7?v=ATCC
    Average 99 stars, based on 66 article reviews
    primary peripheral blood cd14 monocytes - by Bioz Stars, 2026-07
    99/100 stars

    Images



    Similar Products

    primary peripheral blood cd14 monocytes  (ATCC)
    99
    ATCC primary peripheral blood cd14 monocytes
    Primary Peripheral Blood Cd14 Monocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+peripheral+blood+cd14+monocytes/pm41913215-62-0-7?v=ATCC
    Average 99 stars, based on 1 article reviews
    primary peripheral blood cd14 monocytes - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    primary cd14 human peripheral blood monocytes hpbms  (PromoCell)
    93
    PromoCell primary cd14 human peripheral blood monocytes hpbms
    A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated <t>CD14</t> + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).
    Primary Cd14 Human Peripheral Blood Monocytes Hpbms, supplied by PromoCell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+peripheral+blood+cd14+monocytes/pmc12847883-228-2-13?v=PromoCell
    Average 93 stars, based on 1 article reviews
    primary cd14 human peripheral blood monocytes hpbms - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    atcc product code  (ATCC)
    99
    ATCC atcc product code
    A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated <t>CD14</t> + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).
    Atcc Product Code, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+peripheral+blood+cd14+monocytes/pmc12726827-141-10-13?v=ATCC
    Average 99 stars, based on 1 article reviews
    atcc product code - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    peripheral blood cd14 monocytes pbmc  (ATCC)
    99
    ATCC peripheral blood cd14 monocytes pbmc
    A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated <t>CD14</t> + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).
    Peripheral Blood Cd14 Monocytes Pbmc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+peripheral+blood+cd14+monocytes/pmc12726827-141-2-10?v=ATCC
    Average 99 stars, based on 1 article reviews
    peripheral blood cd14 monocytes pbmc - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    primary peripheral blood cd14 monocytes pbmc human atcc product code  (ATCC)
    99
    ATCC primary peripheral blood cd14 monocytes pbmc human atcc product code
    A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated <t>CD14</t> + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).
    Primary Peripheral Blood Cd14 Monocytes Pbmc Human Atcc Product Code, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+peripheral+blood+cd14+monocytes/10__7554_slash_elife__108465-650-23-30?v=ATCC
    Average 99 stars, based on 1 article reviews
    primary peripheral blood cd14 monocytes pbmc human atcc product code - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    human  (ATCC)
    99
    ATCC human
    A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated <t>CD14</t> + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).
    Human, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+peripheral+blood+cd14+monocytes/pm40450320-280-6-7?v=ATCC
    Average 99 stars, based on 1 article reviews
    human - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    primary peripheral bloodcd14 monocytes  (ATCC)
    99
    ATCC primary peripheral bloodcd14 monocytes
    A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated <t>CD14</t> + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).
    Primary Peripheral Bloodcd14 Monocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+peripheral+blood+cd14+monocytes/pm40450320-280-0-7?v=ATCC
    Average 99 stars, based on 1 article reviews
    primary peripheral bloodcd14 monocytes - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated CD14 + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).

    Journal: Cell Death & Disease

    Article Title: Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness

    doi: 10.1038/s41419-025-08363-9

    Figure Lengend Snippet: A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated CD14 + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).

    Article Snippet: In addition, primary CD14 + human peripheral blood monocytes (hPBMs) were purchased from PromoCell (#C-14110) as a single-donor cell pellet stored in RNA later ® .

    Techniques: Expressing, Derivative Assay